Santen Pharmaceutical Co., Ltd.
Research Santen Pharmaceutical Co., Ltd. (4536.T) on Bullrun: market cap JPY 558.39B, P/E 14.6, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4536.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyJPY
- Market capJPY 558.39B
- P/E14.6
- Dividend yield2.3%
- Financial periodFY2026
- RevenueJPY 291.62B
- Revenue growth-2.8%
- Net incomeJPY 37.37B
- Gross margin58.2%
Valuation Snapshot
latest market cap is JPY 558.39B; P/E is 14.6; dividend yield is 2.3%.
Peer valuation comparison
Latest P/E is 14.63x versus a Healthcare sector median of 21.69x (32.6% below).
Latest dividend yield is 2.32% versus a Healthcare sector median of 2.41% (3.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 291.62B | JPY 37.37B | n/a | 58.2% | 113.8 | JPY 80.88B | n/a | JPY 296.99B |
| FY2025 | JPY 300.00B | JPY 36.26B | n/a | 57.0% | 103.68 | JPY 93.00B | n/a | JPY 286.24B |
| FY2024 | JPY 301.97B | JPY 26.64B | JPY 61.96B | 59.2% | 72.37 | JPY 94.58B | n/a | JPY 306.06B |
| FY2023 | JPY 279.04B | -JPY 14.95B | JPY 12.56B | 59.5% | -38.6 | JPY 57.90B | n/a | JPY 293.98B |
| FY2022 | JPY 266.26B | JPY 27.22B | JPY 10.20B | 58.8% | 67.97 | JPY 83.01B | n/a | JPY 337.49B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 558.39B | 14.6 | 2.4% | 42 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 42 JPY, yield 2.3%.
| Year | Dividends/share |
|---|---|
| FY2026 | 40 JPY |
| FY2025 | 38 JPY |
| FY2024 | 34 JPY |
| FY2023 | 32 JPY |
| FY2022 | 0.17 JPY |
About Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Santen Pharmaceutical Co., Ltd.'s market cap?
Santen Pharmaceutical Co., Ltd.'s market capitalization is JPY 558.39B.
What is Santen Pharmaceutical Co., Ltd.'s P/E ratio?
Santen Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 14.6.
Does Santen Pharmaceutical Co., Ltd. pay a dividend?
Santen Pharmaceutical Co., Ltd. has a dividend yield of 2.3%.
What does Santen Pharmaceutical Co., Ltd. do?
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments.